Pieter Cullis made significant contributions to the development of lipid nanoparticles (LNPs) for the delivery of nucleic acids in gene therapy. In 2005 he developed LNP technology for RNA-based drugs, leading to the siRNA drug patisiran. In 2009 he cofounded Acuitas Therapeutics, collaborating on mRNA vaccine development, which included working with BioNTech and Pfizer on the generation of a COVID-19 vaccine.
verifiedCite
While every effort has been made to follow citation style rules, there may be some discrepancies.
Please refer to the appropriate style manual or other sources if you have any questions.
Select Citation Style